 The European Commission has approved Swedish Orphan Biovitrum AB OTC: BIOVF - Apellis Pharmaceuticals Incs NASDAQ: APLS Aspaveli pegcetacoplan for paroxysmal nocturnal hemoglobinuria PNH. The approval covers anemic patients after treatment with a C5 inhibitor for at least three months. 